Tag Archives: AVERROES

X-VERT: rivaroxaban▼ an alternative to VKA in cardioversion for AF Watch Professor Keith Fox, Chairman of the ESC programme committee discussing the relevance of X-VERT and other studies for UK practice in our podcast from the ESC Oral anticoagulant therapy with rivaroxaban is an alternative to vitamin K antagonists (VKAs) in patients with AF who are undergoing elective cardioversion according to the results of the X-VERT study.1 In addition, rivaroxaban may potentially have one important advantage over VKAs, with a shorter time to cardioversion, the study suggests. Professor Riccardo Cappato (University of Milan, Italy), the co-principal

The trial was stopped after a predefined interim analysis by the independent data monitoring committee “revealed clear evidence of a clinically important reduction in stroke and systemic embolism”, a company statement announced. The AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) study included 5,600 patients with all types of atrial fibrillation who were intolerant of or unsuitable for warfarin. They were randomised to 5 mg of apixaban or 81–324 mg of aspirin for up to 36 months. The primary efficacy outcome is the time from the first dose of the study drug to the first occurrence of ischaemic stroke, haemorrhagic